No disclosed relationships extracted for BBLGyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Nothing on the wire mentions BBLG yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How BBLG has moved on past release days vs its typical ±4.7% day, and how often it closed up. Computed from daily closes — not a forecast.